Prediction of the permeability of antineoplastic agents through nitrile medical gloves by zone classification based on their physicochemical properties

Table 1 Antineoplastic agents used in this study

Antineoplastic agents	Brand name	C_Test (mg/mL)	MW^a)	LogP^b)	Ref.^c)
Carboplatin	PARAPLATIN® INJECTION (Bristol-Myers Squibb K.K.)	10	371.25	−0.46	[16]
Carmustine	Carmusutin (≥ 98%) (Sigma-Aldrich)	3.3	214.06	1.53	[17]
Cisplatin	Randa® Inj. 10 mg/20 mL (Nippon Kayaku Co., Ltd.)	0.5	300.5	−2.19	[17]
Cyclophosphamide monohydrate	Endoxan® 100 mg (Shionogi & Co., Ltd.)	20	261.1^d)	0.6	[17]
Doxorubicin Hydrochloride	ADRIACIN® Injection 10 (Aspen Japan Co., Ltd)	10	543.5^e)	1.4	[18]
Etoposide	Lastet® Inj. 100 mg/5 mL (Nippon Kayaku Co., Ltd.)	20	588.6	0.6	[17]
Fluorouracil	5-FU Injection 250 Kyowa (Kyowa Hakko Kirin Co., Ltd.)	50	130.8	−1.0	[19]
Ifosfamide	Ifomide® (Shionogi & Co., Ltd.)	40	261.09	0.86	[20]
Oxaliplatin	ELPLAT® I.V.INFUSION SOLUTION 100 mg (Yakult Honsha Co.,Ltd.)	5	397.29	− 1.6	[21]
Paclitaxel	TAXOL® INJECTION 30 mg (Bristol-Myers Squibb K.K.)	6	853.9	3.7	[22]

^a)molecular weight, ^b)logarithm of octanol-water partition coefficient, ^c)data source of LogP values, ^d)as anhydride, ^e)as free base

ISSN: 2055-0294